Search research articles
Contact Us
Filters
Showing results (361-370 of 418) with videos related to
Page
of 42
Sort By:
The New England Journal of Medicine
|
March 5, 2025
Remibrutinib in Chronic Spontaneous Urticaria
Martin Metz, Ana Giménez-Arnau, Michihiro Hide, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Joshua Burshtein, April Armstrong, May Chow, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
The Journal of Clinical and Aesthetic Dermatology
|
January 25, 2021
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities
Ryan Rivera-Oyola, Roselyn Stanger, Graham H Litchman, et al.
The British Journal of Dermatology
|
January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Mark Lebwohl, Richard B Warren, Howard Sofen, et al.
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
JAAD International
|
February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)
Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Journal of the American Academy of Dermatology
|
April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter, Alice Gottlieb, Steven R Feldman, et al.
Journal of the American Academy of Dermatology
|
January 16, 2018
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Scott M Whitlock, Clinton W Enos, April W Armstrong, et al.
The Journal of Dermatology
|
June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Luis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Page
of 42
Search research articles
Search
Showing results (361-370 of 418) with videos related to
Sort By:
Page
of 42
The New England Journal of Medicine
|
March 5, 2025
Remibrutinib in Chronic Spontaneous Urticaria
Martin Metz, Ana Giménez-Arnau, Michihiro Hide, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Joshua Burshtein, April Armstrong, May Chow, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
The Journal of Clinical and Aesthetic Dermatology
|
January 25, 2021
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities
Ryan Rivera-Oyola, Roselyn Stanger, Graham H Litchman, et al.
The British Journal of Dermatology
|
January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Mark Lebwohl, Richard B Warren, Howard Sofen, et al.
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
JAAD International
|
February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)
Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Journal of the American Academy of Dermatology
|
April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter, Alice Gottlieb, Steven R Feldman, et al.
Journal of the American Academy of Dermatology
|
January 16, 2018
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Scott M Whitlock, Clinton W Enos, April W Armstrong, et al.
The Journal of Dermatology
|
June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Luis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Page
of 42